Exicure, Inc. (Nasdaq: XCUR) plans to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under a License and Collaboration Agreement between the two parties.

The milestone was triggered by the completion of a Phase 2 clinical trial of Burixafor (GPC-100), which included the formal submission of a Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.

The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of approximately $1.0 million.

On July 31, 2026, Exicure submitted a Listing of Additional Shares Notification to the Nasdaq Stock Market in connection with the issuance and delivered treasury issuance instructions to its transfer agent, Equiniti Trust Company, LLC.

"Settling this milestone payment through the issuance of common stock will allow Exicure to preserve cash and maintain financial flexibility as we continue to pursue our operational and strategic priorities," said Jung Soo Kim, Chief Executive Officer of Exicure.

The issuance is subject to customary Nasdaq and transfer agent review and processing procedures. Exicure said it intends to provide an update following completion of the issuance.